



1005 Rec'd PCT/PTO 19 MAR 2002

PATENT

Case Docket No. NIH220.001APC

Date: March 15, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : NABEL, et al.
Appl. No. : 09/913,909
Filed : August 17, 2001
For : IMMUNIZATION FOR EBOLA
VIRUS INFECTION
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked
attachments are being deposited with the United States
Postal Service as first class mail in an envelope addressed
to: United States Patent and Trademark Office, P.O.
Box 2327, Arlington, VA 22202, on

March 15, 2002

(Date)

Nancy W. Wensko, Reg. No. 36,298

TRANSMITTAL LETTER


United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

ATTENTION: APPLICATION BRANCH

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with thirty seven (37) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Nancy W. Wensko
Registration No. 36,298
Attorney of Record



NIH220.001APC

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	NABEL, et al.)	Group Art Unit Unknown
)	
App. No.	:	09/913,909)	
)	
Filed	:	August 17, 2001)	
)	
For	:	IMMUNIZATION FOR EBOLA)	
		VIRUS INFECTION)	
)	
Examiner	:	Unknown)	

INFORMATION DISCLOSURE STATEMENT

United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Enclosed is form PTO-1449 listing references that are also enclosed. This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 3/13/02

By: 

Nancy W. Wensko
Registration No. 36,298
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(805) 547-5585

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NIH220.001APCAPPLICATION NO.
09/913,909INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

MAR 19 2002

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Nabel, et al.FILING DATE
August 17, 2001GROUP
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

1	Arai, H., et al. (1997) <i>Inhibition of the alloantibody response by DC95 ligand</i> . Nature Med. 3:843-848.
2	Border, W.A., et al. (1995) <i>Targeting TGF-β for treatment of disease</i> . Nature Med. 1:1000-1001.
3	Bowen, E.T.W., et al. (1977) <i>Viral haemorrhagic fever in southern Sudan and northern Zaire</i> . Lancet 1:571-573.
4	Bukreyev, A. A., et al. (1993) <i>The GP-protein of Marburg virus contains the region similar to the 'immunosuppressive domain' of oncogenic retrovirus P15E proteins</i> . FEBS. Lett. 323:183-187.
5	Cianciolo, G.J., et al. (1985) <i>Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins</i> . Science 230:453-455.
6	Clegg, J.C.S., et al. (1997) <i>Vaccines against arenaviruses and filoviruses</i> . New Generation Vaccines, (eds Levine, M.M., et al.) 749-765 (Marcel Dekker, New York).
7	Corr, M., et al. (1996) <i>Gene Vaccination with Naked Plasmid DNA: Mechanism of CTL priming</i> . J. Exp. Med. 184:1555-1560.
8	Davis, L.S., et al. (1995) <i>Measurement of human and murine interleukin 2 and interleukin 4</i> . Current Protocols in Immunology (eds. Coligan, J.E., et al.) 6.3.1- 6.3.12 (John Wiley & Sons, NY).
9	Doe, B., et al. (1996) <i>Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells</i> . Proc. Natl. Acad. Sci. USA 93:8578-8583.
10	Doolan, D.L., et al. (1996) <i>Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8⁺ T Cell-, Interferon γ-, and Nitric Oxide-Dependent immunity</i> . J. Exp. Med. 183:1739-1746.
11	Harris, D.T., et al. (1987) <i>Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E</i> . J. Immunol. 138:889-894. Iwasaki, A., et al. (1997) <i>The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites</i> . J. Immunol. 159:11-14.
12	Iwasaki, A., et al. (1997) <i>The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites</i> . J. Immunol. 159:11-14.
13	Jahrling, P.B., et al. (1996) <i>Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses</i> . Arch. Virol. Suppl. 11:135-140.

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NIH220.001APC	APPLICATION NO. 09/913,909
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Nabel, et al.	
		FILING DATE August 17, 2001	GROUP Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	14	Jorgensen, J.L., et al. (1992) <i>Molecular components of T-cell recognition</i> . Annu. Rev. Immunol. 10:835-873.
	15	Ksiazek, T.G., et al. (1991) <i>Laboratory diagnosis of filovirus infections in nonhuman primates</i> . Lab. Animal 20:334-46.
	16	Ksiazek, T.G., et al. (1992) <i>Enzyme immunoassay for Ebola virus antigens in tissues of infected primates</i> . J. Clin. Microbiol. 30:947-950.
	17	Manthorpe, M., et al. (1993) <i>Gene therapy by intramuscular injection of plasmid DNA: Studies on firefly luciferase gene expression in mice</i> . Hum. Gene Ther. 4:419-431.
	18	McCormick, J.B., et al. (1983) <i>Biologic differences between strains of Ebola virus from Zaire and Sudan</i> . J. Infect. Dis. 147:264-267.
	19	Monaco, J.J. (1992) <i>A molecular model of MHC class-I-restricted antigen processing</i> . Immunol. Today 13:173-179.
	20	Ohno, T., et al. (1997) <i>Combination gene transfer to potentiate tumor regression</i> . Gene Thera 4:361-366.
	21	Peters, C.J., et al. (1994) <i>Filoviruses as emerging pathogens</i> . Semin. Virol. 5:147-154.
	22	Peters, C.J., et al. (1996) <i>Filoviridae: Marburg and Ebola Viruses</i> . Fields Virology (eds. Fields, B.N., et al.) 1161-1176, Lippincott-Raven, Philadelphia.
	23	Raz, E., et al. (1993) <i>Systemic immunological effects of cytokine genes injected into skeletal muscle</i> . Proc. Natl. Acad. Sci. USA 90:4523-4527.
	24	Raz, E., et al. (1994) <i>Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses</i> . Proc. Natl. Acad. Sci. USA 91:9519-9523.
	25	Sanchez, A., et al. (1989) <i>The Nucleoprotein gene of Ebola virus: Cloning, sequencing, and in Vitro expression</i> . Virology 170:81-91.
	26	Sanchez, A., et al. (1993) <i>Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus</i> . Virus. Res 29:215-240.
	27	Sanchez, A., et al. (1996) <i>The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing</i> . Proc. Natl. Acad. Sci. USA 93:3602-3607.
	28	Sedegah, M., et al. (1994) <i>Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein</i> . Proc. Natl. Acad. Sci. USA 91:9866-9870. Ksiazek, T.G. (1991) <i>Laboratory diagnosis of filovirus infections in nonhuman primates</i> . Lab. Animal 20:34-46.
	29	Tan, B.T.G., et al. (1985) <i>Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 la-like antigen: The value of immunohistological screening</i> . Hybridoma 4:115-124.
	30	Tang, D.C., et al. (1992) <i>Genetic immunization is a simple method for eliciting an immune response</i> . Nature 356:152-154.
	31	Tascon, R.E., et al. (1996) <i>Vaccination against tuberculosis by DNA injection</i> . Nature Med. 2:888-892.
	32	Ulmer, J.B., et al. (1993) <i>Heterologous protection against influenza by injection of DNA encoding a viral protein</i> . Science 259:1745-1749.
	33	Volchkov, V.E., et al. (1992) <i>The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses</i> . FEBS, Lett. 305:181-184.
	34	Waisman, A., et al. (1996) <i>Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity</i> . Nature Med. 2:899-905.
	35	Wolff, J.A., et al. (1990) <i>Direct gene transfer into mouse muscle in vivo</i> . Science 247:1465-1468.
	36	Xu, L., et al. (1998) <i>Immunization for Ebola virus infection</i> . Nature Med. 4:37-42.
	37	Zinkernagel, R.M., et al. (1997) <i>The discovery of MHC restriction</i> . Immunol. Today 18:14-17.

O:\DOCS\MCM\MCM-1955.DOC
030702sev

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	